Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 70518-4005

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-4005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr 2 (13)

A mathematical formula for calculating creatinine clearance (CLcr), expressed as [(140 - age in years) × weight in kg] divided by [72 × serum creatinine in mg/dL], with an additional multiplication by 0.85 for female patients. This formula is typically used to estimate kidney function.*

FDA Label Image

Clcr 2 (2)

A data table showing the formula for adjusting creatinine clearance (CLcr) based on body surface area (BSA). It includes the calculation of CLcr in mL/min per 1.73 m² using the patient's BSA in square meters.*

FDA Label Image

Levetiracretam Structural Formula (3)

Chemical structure diagram of levetiracetam, showing its molecular arrangement with annotated chemical groups and bonds typical for the active ingredient levetiracetam.*

FDA Label Image

Figure 1 (4)

A bar chart showing percentage of patients across three groups: Placebo (7.4%), Immediate-release levetiracetam tablets 1000 mg/day (37.1%), and Immediate-release levetiracetam tablets 3000 mg/day (39.6%). The y-axis represents the percentage of patients, and a note indicates statistical significance versus placebo for both levetiracetam groups.*

FDA Label Image

Figure 2 (5)

A vertical bar graph illustrating percentages of patients across three groups: Placebo (6.3%, N=111), Immediate-release levetiracetam tablets 1000 mg/day (20.8%, N=106), and Immediate-release levetiracetam tablets 2000 mg/day (35.2%, N=105). The y-axis shows percentage of patients ranging from 0% to 45%, and bars for levetiracetam groups are marked as statistically significant versus placebo.*

FDA Label Image

Figure 3 (6)

A bar graph showing the percentage of patients for placebo versus immediate-release levetiracetam tablets at 3000 mg/day. The placebo group (N=104) has 14.4% of patients, while the levetiracetam group (N=180) has 39.4%, with a noted statistically significant difference versus placebo.*

FDA Label Image

Figure 4 (7)

A bar graph comparing the percentage of patients in two groups: placebo (N=97) and immediate-release levetiracetam tablets (N=101). The y-axis shows percentage of patients from 0% to 45%. The placebo group has 19.6% patients, while the immediate-release levetiracetam group has 44.6%, with a note indicating statistical significance versus placebo.*

FDA Label Image

Remedy_label (Remedy Label)

Label for LEVETIRACETAM 500 mg extended-release film-coated tablets, oral dosage form, packaged as 30 tablets. The label includes the NDC 70518-4005-00 and is marked RX only. Manufactured by Solco in Cranbury, NJ, and repackaged by RemedyRepack Inc. The label cautions to keep out of reach of children and references storage conditions and directions for use on the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.